Juan Carlos CHAVEZ, Plaintiff-Appellant, v. FLORIDA SP WARDEN, Secretary, Florida Department of Corrections, John Does, Defendants-Appellees.
No. 14-10561
United States Court of Appeals, Eleventh Circuit.
Feb. 12, 2014.
742 F.3d 1267
Non-Argument Calendar.
Before CARNES, Chief Judge, WILSON and MARTIN, Circuit Judges.
CARNES, Chief Judge:
Juan Carlos Chavez kidnapped a nine-year-old boy at gunpoint, anally raped him, verbally taunted and terrorized him, shot him to death, dismembered his body, discarded his body parts in three planters, and then filled those planters with concrete. See Chavez v. State, 832 So.2d 730, 738-41 (Fla.2002). Facing imminent execution, Chavez has filed a lawsuit claiming that he may experience unnecessary pain when the State of Florida executes him by lethal injection. After conducting an evidentiary hearing, the district court denied Chavez‘s request for a temporary restraining order, preliminary injunction, or stay of execution. This is his appeal.1
I. BACKGROUND
Florida‘s revised lethal injection protocol, adopted on September 9, 2013 (2013 Protocol), calls for the sequential intravenous administration of three drugs: (1) 500 milligrams of midazolam hydrochloride, which is meant to serve as an anesthetic; (2) 100 milligrams of vecuronium bromide, a neuromuscular blocking agent that paralyzes voluntary muscles, including the diaphragm, and stops respiration; and (3) 240 milliequivalents of potassium chloride, a naturally occurring salt that induces cardiac arrest by interfering with the heart‘s electrical activity. Chavez also filed a motion for a temporary restraining order, preliminary injunction, or stay of execution (omnibus motion).
Although Chavez‘s amended
Relying on the declaration of his retained expert, anesthesiologist Dr. David Lubarsky, Chavez asserted that midazolam is not typically used in clinical settings, nor FDA-approved for use, as a standalone anesthetic in major surgical procedures because it has no analgesic (pain-relieving) properties; that it can trigger “paradoxical reactions” which would prevent its sedative properties from taking effect, particularly in those, like himself, who suffer from extreme anxiety or certain other mental disorders; that there is no scientific evidence that 500
Chavez also pointed to published news reports of three recent executions—the Florida executions of William Happ and Askari Abdullah Muhammad, and the Ohio execution of Dennis McGuire—each of which is said to have involved varying degrees of movement after the administration of midazolam. Chavez took thesе reported movements—a momentary head movement in case of Happ, the opening of an eye in the case of Muhammad, and McGuire appearing to gasp for air—as indicating that midazolam is not effective in rendering an inmate unconscious and insensate to pain. As a proffered alternative to the use of midazolam, Chavez advocated the use of a barbiturate, either in combination with other drugs or in a single fatal dose, as a more humane method of execution that “would significantly reduce the substantial risk of excruciating pain” allegedly created by the 2013 Protocol. But the only specific barbiturates named anywhere in his amended complaint or omnibus motion were pentobarbital and sodium thiopental, both of which Florida had previously used as the first drug in its lethal injection protocol. Florida initially used sodium thiopental, but as Chavez explained in an appendix to his amended complaint, “international pressure against the death penalty [] resulted in a shortage of sodium thiopental” that forced states with capital punishment “to scramble for an alternative drug.” Florida then selected pentobarbital, but as Chavez conceded in his amended complaint, pentobarbital is no longer available and the “2013 Protocol was created in response to [its] unavailability.”
After an evidentiary hеaring marked by sharply conflicting testimony from Chavez‘s expert, Dr. Lubarsky, and the State‘s expert, Dr. Roswell Lee Evans, the district court denied Chavez‘s omnibus motion for a temporary restraining order, preliminary injunction, or stay of execution because he had not shown a substantial likelihood of success on the merits of his claims, both on the merits themselves and as to the statute of limitations defense the State had asserted. The court rejected Dr. Lubarsky‘s testimony as “essentially speculative and insufficient to meet [Chavez‘s] burden,” and instead credited Dr. Evans’ testimony that 500 milligrams of midazolam—forty times the dosage typically used in clinical settings—would not only induce a deep anesthetic statе in which an inmate would be rendered insensate, unconscious, and incapable of feeling pain, but would ultimately result in respiratory arrest, cardiac arrest, and death. Doc. 50 at 22-25, 33, 35. Based on Dr. Evans’ testimony, the court concluded that the “massive dose [of midazolam] required by the Florida protocol ... will render the individual insensate to noxious stimuli by placing the individual in an anesthetic state, unable to discern pain,” that its effects would be “quite similar to that of sodium thiopental or pentobarbital on consciousness,” and that it “would result in a cascade effect with the whole body rapidly starting to shut down” until an inmate‘s “ultimate[] death.” Id. at 25, 35.
The court, again crediting Dr. Evans’ testimony, also rejectеd Chavez‘s contention that midazolam, in the massive dose stipulated in the 2013 Protocol, carries a substantial risk of paradoxical reactions, and his contention that the bodily movements reported in the executions of Happ, Muhammad, and McGuire demonstrated a
Chavez timely appealed to us the district court‘s denial of his omnibus motion.3 We have jurisdiction under
II. DISCUSSION
A preliminary injunction is appropriate if the movant demonstrates all of these elements: (1) a substantial likelihood of success on the merits; (2) that the preliminary injunction is necessary to prevent irreparable injury; (3) that the threatened injury outweighs thе harm the preliminary injunction would cause the other litigant; and (4) that the preliminary injunction would not be averse to the public interest. Parker v. State Bd. of Pardons & Paroles, 275 F.3d 1032, 1034-35 (11th Cir.2001). We review a district court‘s denial of a motion for a preliminary injunction only for an abuse of discretion. See Valle v. Singer, 655 F.3d 1223, 1225 (11th Cir.2011).
Capital punishment, including capital punishment by lethal injection, generally is constitutional. See Baze v. Rees, 553 U.S. 35, 47, 128 S.Ct. 1520, 1529, 170 L.Ed.2d 420 (2008) (plurality opinion).4
Chavez has not established a substantial likelihood of success on the merits of his
III. THE MOTION FOR A STAY OF EXECUTION
The standard for granting a motion for a stay of execution mirrors that for granting a preliminary injunction which, in this specific context, is a stay of execution. A stay should not be granted unless the inmate establishes a substantial likelihood of success on the merits. Valle, 655 F.3d at 1225. For the reasons we have already discussed, Chavez has failed to show a substantial likelihood of success on the merits of his claims. For that reason, his motion for a stay of execution is due to be denied without regard to the other three requirements for issuance of one. Id.
IV. CONCLUSION
The district court‘s order denying a preliminary injunction is AFFIRMED. The motion for a stay of execution is DENIED.
CARNES, Chief Judge, concurring:
I concur in all of the Court‘s opinion and write separately to discuss an independently adequate alternative reason why Chavez has failed to show a substantial likelihood of success on his claim that Florida‘s use of midazolam hydrochloride in its 2013 Protocol violates the
The Supreme Court held in Baze v. Rees, 553 U.S. 35, 128 S.Ct. 1520, 170 L.Ed.2d 420 (2008) (plurality opinion), that to establish an
[T]he proffered alternatives must effectively address a “substantial risk of serious harm.” To qualify, the alternative procedure must be feasible, readily implemented, and in fact significantly reduce a substantial risk of severe pain. If a State refuses to adopt such an alternative in the face of these documented advantages, without a legitimate penological justification for adhering to its current method of execution, then a State‘s refusal to change its method can be viewed as “cruel and unusual” under the
Eighth Amendment .
Id. at 52, 128 S.Ct. at 1532 (citation omitted). As is true with every other element of a claim, the burden of proof on all aspects of the alternativе drug requirement is on the plaintiff inmate.
An inmate obviously cannot begin to prove that there is an “available,” “feasible,” and “readily implemented” alternative drug that will “in fact significantly reduce a substantial risk of severe pain,” id. at 52, 61, 128 S.Ct. at 1532, 1537, without identifying a sрecific drug that meets those requirements. Chavez has failed to do that. While he attacks the use of midazolam in Florida‘s three-drug lethal injection protocol, and broadly advocates for the adoption of a single-drug protocol consisting of a fatal dose of a barbiturate, he has not specifically identified any particular barbiturate that is even allegedly “available,” “feasible,” and can be “readily implemented” by the State of Florida.
Chavez‘s filings in the district court did not contend that there is any specific alternative drug that is actually available for use by the State of Florida. In his amended complaint, the appendices to that complаint, and his omnibus motion, Chavez mentioned two barbiturates—pentobarbital and sodium thiopental—that could be used in place of midazolam, but he admitted that neither drug was available for use in executions. Chavez conceded in his complaint that Florida‘s “2013 Protocol was created in response to the unavailability of pentobarbital.” Doc. 15 at 6 (emphasis added). And in an appendix to his amended complaint, Chavez admitted that sodium thiopental is not available for use in lethal injections either. The appendix contains a “Request for Additional Public Records from the Florida Department of Corrections Pursuant to
In 2010, international pressure against the death pеnalty resulted in a shortage of sodium thiopental and the states that employ capital punishment had to scramble for an alternative drug. On June 8, 2011, Florida followed the path of other states when it issued new lethal injection procedures substituting the barbiturate pentobarbital (Nembutal) for sodium thiopental.
Doc. 20 at 6.
Instead of alleging that pentobarbital and sodium thiopental are “available,” “feasible,” and can be “readily implemented” by the State of Florida in place of midazolam, Chavez represented to the district court in his filings that they are not available for use in lethal injections. Even if he had not made those concessions, however, his claim would still fail for the samе reasons. An inmate must not only plead that a specifically named alternative drug is “available,” “feasible” and can be “readily implemented” in the challenged lethal injection protocol, he must also prove it. Chavez introduced not one jot, tittle, or iota of evidence that pentobarbital or sodium thiopental is available and can be readily obtained by the State of Florida for use in executing him or any other death-row inmate.1
Throughout the district court proceedings, the most Chavez did in the way of demonstrating an adequate alternative to the 2013 Protocol was asserting that a single-drug protocol was a “feasible, readily implemented alternative procedure.” He accurately summarized the extent of his contentions at the evidentiary hearing when he said: “We‘ve offered the alternatives, the one-drug protocol.” But he never identified that one drug nor even suggested how Florida could obtain it for use in executions. Chavez has not come close to satisfying his burden of proving the existence of an “available,” “feasible,” and “readily implemented” alternative to midazolam hydrochloride, let alone one that will significantly reduce a substantial risk of severe pain. This is another reason he has failed to еstablish a substantial likelihood of success on the merits of his
WILSON, Circuit Judge, concurring:
I agree that the district court properly found that Chavez failed to demonstrate a substantial likelihood of success on the merits of his claims and is thus not entitled to a stay of his execution. Therefore, I concur in the majority opinion. I write separately to underscore that the question of whether a significant change has occurred to a state‘s lethal injection protocol is a fact-intensive inquiry for which an evidentiary hearing is especially important. The district judge in this case properly conducted an evidentiary hearing and thoroughly studiеd the parties’ filings and exhibits and the governing legal principles. Indeed, while the district court concluded that expert anesthesiologist Dr. Lubarsky‘s testimony was ultimately speculative and insufficient to meet Chavez‘s burden, nothing prevents a future inmate from presenting an anesthesiologist or expert to
MARTIN, Circuit Judge, concurring in judgment:
In Mr. Chavez‘s case, the District Court has made the factual finding that Florida‘s “protocol change substituting midazolam for the first drug in the three-drug protocol is not a substantial change to the рrotocol.” This finding is not clearly erroneous based on the record before the District Court, so I am compelled to affirm the District Court‘s Order denying a preliminary injunction and stay of Mr. Chavez‘s execution.
I write separately to emphasize the fact-intensive nature of the District Court‘s decision in this case and to commend the District Court for holding an evidentiary hearing before concluding that Mr. Chavez “has not shown a substantial likelihood of success on the merits of his claims because they are barred by Florida‘s four-year statute of limitations.” Because I view the statute of limitations issue as dispositive to Mr. Chavez‘s
Where, as here, the state raises a valid statute of limitations defense to a
Mr. Chavez filed his
At the beginning of the evidentiary heаring, the District Court heard arguments on preliminary matters, including arguments about the necessity of even having an evidentiary hearing. Mr. Chavez‘s counsel argued that his expert, Dr. Lubarsky would testify, consistent with his earlier filed affidavit, that Florida‘s September 2013 changes to its lethal injection protocol worked a “substantial change” sufficient to overcome any statute of limitations bar. Mr. Chavez‘s counsel acknowledged at the time that “if we do not prevail on a substantial change, then obviously the statute of limitations issue is foreclosed, but we will make the case today that this was a substantial change.” Mr. Chavez‘s arguments prompted the District Court to ask the state the following question: “[I]s not that determinаtion a fact intensive determination as to whether or not there‘s been a substantial change? And as I understand [the state‘s] argument, the statute of limitations rests on whether or not there has been a substantial change?” The state answered “Yes” and argued that “merely substituting” “one anesthetizing drug in the three-drug protocol does not restart your statute of limitations.” After hearing additional argument, the District Court denied the state‘s motion for the Court to reconsider its order setting an evidentiary hearing, explaining that the issues raised by the state “are all fact dependent.” I could not agree more with the District Court‘s decision that an evidentiary hearing was necessary.
It is well-settled that “a method of еxecution claim accrues on the later of the date on which state review is complete, or the date on which the capital litigant becomes subject to a new or substantially changed execution protocol.” McNair v. Allen, 515 F.3d 1168, 1174 (11th Cir.2008). Mr. Chavez‘s state case became final in 2003 with the denial of certiorari review by the United States Supreme Court. See Chavez v. Florida, 539 U.S. 947, 123 S.Ct. 2617, 156 L.Ed.2d 637 (2003).1 In order to overcome Florida‘s statute of limitations defense, Mr. Chavez “must show that he filed his
Mr. Chavez‘s motion for temporary restraining order, preliminary injunction and stay in the District Court alleged his
Significantly, Mr. Chavez supported his factual allegations with a declaration from
We have said that “[w]hether a significant change has occurred in a state‘s method of execution is a fact-dependent inquiry, which we have treated as such in each of our recent cases addressing the lethal injection protocols of Alabama, Georgia and Florida.” Arthur, 674 F.3d at 1260 (emphasis added). As we emphasized in Arthur, any conclusion that the substitution of one drug for another in a lethal injection protocol does not constitute a “significant change” is necessarily “premised on the spеcific factual allegations and/or evidence presented and considered” in each case. Id. One
All this is to sаy, the District Court should be commended for its cautious and deliberate approach to deciding the disputed factual issues concerning Florida‘s new midazolam drug protocol. Given the fact dependent nature of the District Court‘s ruling on the issue of whether Mr. Chavez demonstrated a significant change to the protocol, as well as the deference owed District Court fact findings made after an evidentiary hearing, I am compelled to defer to the District Court‘s conclusion that Mr. Chavez has not shown a likelihood of success on the merits of his claims because they are barred by Florida‘s statute of limitations. The District Court‘s fact finding on this issue was not clearly erroneous.
